ClinicalTrials.gg

Program

RAP-219

A development code.

Its studies are mostly in Seizures · Mania · Epilepsies, Partial, led by Rapport Therapeutics.

Furthest: phase 3, since Apr 16, 20265 company-led studies, 3 open or runningNext primary completion: Feb 3, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rapport Therapeutics53 open or runningphase 3since Apr 16, 2026Apr 17, 2024Feb 3, 2028phase 2 · NCT07219407

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2024First study: phase 2 study in SeizuresFirst studyNCT06377930 · 30 enrolled · United States
  2. May 30, 2025Phase 2 study in ManiaNCT07046494 · 253 enrolled · United States
  3. Oct 8, 2025Phase 2 study in Epilepsies, PartialNCT07219407 · 30 planned · United States
  4. Apr 16, 2026Phase 3 study in SeizuresPhase 3 reachedNCT07563881 · 333 planned · United States, Australia, South Korea and more
  5. May 11, 2026Phase 3 study in SeizuresNCT07594119 · 312 planned · United States, Australia, South Korea

Ahead

  1. Feb 3, 2028Primary completion: phase 2 study in Epilepsies, PartialNCT07219407
  2. Jul 2029Primary completion: phase 3 study in SeizuresNCT07594119
  3. Jul 2029Primary completion: phase 3 study in SeizuresNCT07563881

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07594119Seizures · United States, Australia, South Korea3RecruitingJul 2029312
NCT07563881Seizures · United States, Australia, South Korea and more3RecruitingJul 2029333
NCT07219407Epilepsies, Partial · United States2RecruitingFeb 3, 202830
NCT07046494Mania · United States2CompletedAug 5, 2026253
NCT06377930Seizures · United States2CompletedSep 26, 202530

How it is read

Names in the registry

  • “RAP-219”, 7 entries

Codes read as this program: RAP219.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.